Aberdeen Group plc Raises Stake in Zoetis Inc. $ZTS

Aberdeen Group plc grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,155,604 shares of the company’s stock after purchasing an additional 59,245 shares during the period. Aberdeen Group plc owned approximately 0.26% of Zoetis worth $179,720,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Davis Rea LTD. boosted its position in shares of Zoetis by 96.6% during the 2nd quarter. Davis Rea LTD. now owns 41,239 shares of the company’s stock worth $6,431,000 after purchasing an additional 20,268 shares in the last quarter. Blue Zone Wealth Advisors LLC boosted its position in shares of Zoetis by 8.8% in the 2nd quarter. Blue Zone Wealth Advisors LLC now owns 32,626 shares of the company’s stock worth $5,088,000 after buying an additional 2,646 shares in the last quarter. PDS Planning Inc boosted its position in shares of Zoetis by 11.6% in the 2nd quarter. PDS Planning Inc now owns 2,607 shares of the company’s stock worth $407,000 after buying an additional 270 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Zoetis by 11.8% in the 2nd quarter. Blue Trust Inc. now owns 5,854 shares of the company’s stock worth $913,000 after buying an additional 616 shares in the last quarter. Finally, Galvin Gaustad & Stein LLC boosted its position in shares of Zoetis by 6.0% in the 2nd quarter. Galvin Gaustad & Stein LLC now owns 68,718 shares of the company’s stock worth $10,717,000 after buying an additional 3,872 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 1.6%

Shares of ZTS stock opened at $141.05 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a market capitalization of $62.51 billion, a price-to-earnings ratio of 24.28, a PEG ratio of 2.30 and a beta of 0.90. The firm has a 50-day moving average price of $149.24 and a 200 day moving average price of $154.46.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the previous year, the business earned $1.56 EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s payout ratio is presently 34.42%.

Analysts Set New Price Targets

ZTS has been the topic of several recent research reports. Argus reiterated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.